ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference
July 31 2018 - 4:30PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that the Company will present at the upcoming
Canaccord Genuity Growth Conference. The presentation is scheduled
for 8:30 a.m. ET on August 8, 2018.
A webcast of the presentation will be accessible live through
the “Investors” section of the Company’s website,
www.immunogen.com; a replay will be available in the same location
for approximately two weeks.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug
conjugates (ADCs) to improve outcomes for cancer patients. By
generating targeted therapies with enhanced anti-tumor activity and
favorable tolerability profiles, we aim to disrupt the progression
of cancer and offer our patients more good days. We call this our
commitment to “target a better now.” Our lead product candidate,
mirvetuximab soravtansine, is in a Phase 3 study for folate
receptor alpha (FRα)-positive platinum-resistant ovarian cancer,
and in Phase 1b/2 testing in combination regimens. Our novel IGN
candidates for hematologic malignancies, IMGN779 and IMGN632, are
in Phase 1 studies.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180731005741/en/
INVESTOR RELATIONS CONTACTImmunoGen, Inc.Sarah Kiely,
781-895-0600sarah.kiely@immunogen.comorMEDIA
CONTACTImmunoGen, Inc.Courtney O’Konek,
781-895-0600courtney.okonek@immunogen.comorFTI ConsultingRobert
Stanislaro, 212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024